The Sir2 family of enzymes or sirtuins are known as nicotinamide adenine dinucleotide (NAD)-dependent deacetylases 1 and have been implicated in the regulation of transcription, genome stability, metabolism and lifespan 2, 3 . However, four of the seven mammalian sirtuins have very weak deacetylase activity in vitro. Here we show that human SIRT6 efficiently removes long-chain fatty acyl groups, such as myristoyl, from lysine residues. The crystal structure of SIRT6 reveals a large hydrophobic pocket that can accommodate long-chain fatty acyl groups. We demonstrate further that SIRT6 promotes the secretion of tumour necrosis factor-a (TNF-a) by removing the fatty acyl modification on K19 and K20 of TNF-a. Protein lysine fatty acylation has been known to occur in mammalian cells, but the function and regulatory mechanisms of this modification were unknown. Our data indicate that protein lysine fatty acylation is a novel mechanism that regulates protein secretion. The discovery of SIRT6 as an enzyme that controls protein lysine fatty acylation provides new opportunities to investigate the physiological function of a protein post-translational modification that has been little studied until now.
The Sir2 family of enzymes or sirtuins are known as nicotinamide adenine dinucleotide (NAD)-dependent deacetylases 1 and have been implicated in the regulation of transcription, genome stability, metabolism and lifespan 2, 3 . However, four of the seven mammalian sirtuins have very weak deacetylase activity in vitro. Here we show that human SIRT6 efficiently removes long-chain fatty acyl groups, such as myristoyl, from lysine residues. The crystal structure of SIRT6 reveals a large hydrophobic pocket that can accommodate long-chain fatty acyl groups. We demonstrate further that SIRT6 promotes the secretion of tumour necrosis factor-a (TNF-a) by removing the fatty acyl modification on K19 and K20 of TNF-a. Protein lysine fatty acylation has been known to occur in mammalian cells, but the function and regulatory mechanisms of this modification were unknown. Our data indicate that protein lysine fatty acylation is a novel mechanism that regulates protein secretion. The discovery of SIRT6 as an enzyme that controls protein lysine fatty acylation provides new opportunities to investigate the physiological function of a protein post-translational modification that has been little studied until now.
It was recently demonstrated that Sirt5, one of the four sirtuins with weak deacetylase activity, preferentially hydrolyses succinyl and malonyl lysine 4, 5 . The discovery of the novel Sirt5 activity suggested that other sirtuins with weak deacetylase activity may use alternative substrates as well. We therefore set out to investigate whether SIRT6 has any new enzymatic activity. SIRT6 has been reported to be important for DNA repair, transcriptional regulation of genes important for metabolism and immune responses, and for lifespan [6] [7] [8] [9] [10] . In most cases, the biological functions have been linked to the sequence-specific deacetylase activity of SIRT6 on histone H3K9 and K56, but not other peptide sequences 9, 11, 12 . The deacetylase activity of SIRT6 on H3K9 and K56 can indeed be detected in our assay. However, the catalytic efficiency is low ( Table 1 ), indicating that the deacetylase activity may only account for a part of its biological function.
To discover possible novel activity of SIRT6, we synthesized H3K9 peptides with different acyl groups (acetyl, malonyl, succinyl, butyryl, myristoyl and palmitoyl) and assayed these peptides with recombinant SIRT6. SIRT6 can hydrolyse long-chain fatty acyl groups efficiently (Fig. 1a) . The k cat /K m for demyristoylation (1,400 s 21 M
21
) is approximately 300-fold better than that for deacetylation (4.8 s 21 M
). The increased catalytic efficiency comes mainly from the decrease in K m . For deacetylation, the K m is 810 mM, but for demyristoylation, the K m is 3.4 mM. The activity of SIRT6 (a class IV sirtuin) is similar to that of PfSir2A 5 , which was classified as a Class III sirtuin 13 but lacks the conserved Arg and Tyr residues that recognize negatively charged succinyl or malonyl groups 4 . This emphasizes that it is important to examine the activity of each sirtuin experimentally as bioinformatics predictions may not be sufficient.
The conclusion that SIRT6 is better at hydrolysing long-chain fatty acyl groups was also supported by its ability to hydrolyse myristoyl group from other peptide sequences. The deacetylase activity of SIRT6 was reported to be sequence-specific. Only H3K9 and H3K56 acetyl peptides, but not other peptides, were reported to be deacetylated by SIRT6 9, 11, 12 . To test whether the more efficient demyristoylation activity allows SIRT6 to use more peptide substrates, we synthesized acetyl and myristoyl peptides based on the H2B K12 sequence. Consistent with previous reports 9, 11, 12 , the hydrolysis of the acetyl peptide by SIRT6 was undetectable. In contrast, the hydrolysis of the corresponding myristoyl peptide could be readily detected (Fig. 1b) . These results confirm the preference of SIRT6 for long-chain fatty acyl groups.
To determine the structural basis for enhanced SIRT6 activity with fatty acyl peptides, we obtained a crystal structure of SIRT6 in complex with a H3K9 myristoyl peptide and ADP-ribose (ADPR) at 2.2 Å resolution (PDB 3ZG6, Fig. 2a, Supplementary Fig. 1 ). The overall structure is similar to the published SIRT6 structure 14 (PDB 3K35) ( Supplementary Fig. 1 ). Residues 2-10 and 166-174 of SIRT6 are visible in the H3K9 myristoyl bound structure, whereas the corresponding regions are missing in the published SIRT6 structure without peptide bound 14 ( Supplementary Fig. 2 ). The way that H3K9 myristoyl and ADPR bind to SIRT6 is similar to that seen in other ternary complex structures of other sirtuins, such as Sir2Tm in complex with the p53 acetyl peptide and NAD ( Supplementary Fig. 3 ) 15 . The peptide interacts with SIRT6 through many hydrogen-bonding interactions. Similar to what was observed with other sirtuins, including Sirt5, most of the hydrogen bonds come from main chain C5O and N-H of the myristoyl peptide, with the only side chain hydrogen-bonding coming from Trp 11 ( Supplementary Fig. 4) . Therefore, the selectivity for peptide sequences is not high, which is consistent with our enzymology data. The myristoyl group is located in a hydrophobic pocket ( Supplementary Fig. 5 ). The structural data are thus consistent with the biochemical data and provide a reasonable explanation for the preference of SIRT6 for long-chain fatty acyl groups.
The next important question was whether this activity is physiologically relevant. There are a few proteins known to be modified by fatty acyl groups on lysine, although the function of the modification is unclear 16, 17 . One of the fatty acylated proteins is TNF-a 16 , a type II membrane protein with a single transmembrane domain linking the amino-terminal intracellular domain and the carboxy-terminal extracellular domain 18 . When cleaved by proteases, the extracellular domain is released. The released TNF-a can then bind its receptors and induce various signalling pathways 18 . It was reported that SIRT6 can regulate the synthesis of TNF-a, but the mechanism was unclear 19, 20 . We propose that SIRT6 may regulate TNF-a secretion via defatty-acylation.
To test this, we measured the fatty acylation level on TNF-a in SIRT6 wild-type (WT) and knockout (KO) mouse embryonic fibroblast (MEF) cells. Flag-tagged TNF-a was transfected into the cells. The cells were cultured in the presence of an alkyne-tagged fatty acid analogue, Alk14, which can covalently label fatty acylated proteins 21, 22 . TNF-a was immunoprecipitated and conjugated to rhodamine-azide (Rh-N 3 ) using click chemistry (Fig. 3a) . A protein will be fluorescently labelled if it is fatty acylated by Alk14. Because Alk14 can also label cysteine residues 22, 23 , we treated TNF-a with hydroxylamine to remove cysteine fatty acylation (Fig. 3a) . As shown in Fig. 3b , TNF-a from SIRT6 KO MEF cells had significantly increased Alk14 labelling compared to TNF-a from SIRT6 WT MEF cells, indicating that SIRT6 regulates the fatty acylation level on TNF-a. When human SIRT6 WT was overexpressed in SIRT6 KO MEF cells, TNF-a had lower fatty acylation level than TNF-a from cells without overexpression of human SIRT6, whereas overexpression of human SIRT6(H133Y) catalytic mutant did not have much effect on TNF-a fatty acylation ( Fig. 3c ), indicating that enzymatic activity of SIRT6 is required for controlling TNF-a fatty acylation.
To further confirm that fatty acylation occurs on lysine residues of TNF-a, we mutated K19 and K20, the reported sites of myristoylation on TNF-a 16 , to Arg (labelled as 'KR' mutant in Fig. 3b ). The labelling intensities of the mutant from SIRT6 KO MEF cells dropped to background level (Fig. 3b) , confirming that K19 and K20 are the major fatty acylation sites. Furthermore, TNF-a isolated from SIRT6 KO MEF cells can be defatty-acylated in vitro in an NAD-dependent manner (Fig. 3d) . Synthetic TNF-a K19 and K20 myristoyl peptides can be efficiently hydrolysed by SIRT6 (Table 1 ). To rule out that TNF-a could also be regulated by lysine acetylation, we examined the acetylation level using a pan-specific acetyl lysine antibody. No acetylation was detected on K19 and K20 of TNF-a ( Supplementary Fig. 6 ). Thus, SIRT6 regulates the fatty acylation level, but not acetylation level on K19 and K20 of TNF-a.
We next investigated the function of TNF-a fatty acylation on K19 and K20. It was reported that the amount of TNF-a detected in the media of SIRT6 KO cells is less than that in the media of SIRT6 WT cells 20 . This was attributed to the regulation of TNF-a synthesis by SIRT6 20 . Given that SIRT6 regulates lysine fatty acylation, we propose that SIRT6 may regulate the secretion of TNF-a. To test this, Flagtagged TNF-a was transiently transfected into SIRT6 WT and KO MEF cells. The amount of secreted TNF-a in the medium and the amount of TNF-a in the cells were measured by ELISA (Supplementary Fig. 7 ). The percentage of secreted TNF-a was then calculated. TNF-a secretion efficiency was lower in SIRT6 KO MEF cells than in 
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SIRT6 WT MEF cells (Fig. 3E) . The secretion efficiency is due to lysine fatty acylation because the secretion efficiency of TNF-a KR mutant was not affected by SIRT6 knockout. These data indicate that lysine fatty acylation regulates TNF-a secretion and SIRT6 promotes TNF-a secretion by defatty-acylation.
We further investigated whether endogenous TNF-a are also regulated by SIRT6. For this purpose, we used both human THP-1 cells and bone-marrow-derived mouse macrophages. Two SIRT6 knockdown (KD) THP-1 cell lines and one control KD THP-1 cell line were generated (Fig. 3f) . TNF-a from SIRT6 KD cells contained more fatty acylation than TNF-a from the control KD cells (Fig. 3f) . The amount of secreted TNF-a in the medium and the amount of TNF-a in the cells were measured (Supplementary Fig. 8 ) and the percentage of secreted TNF-a was calculated (Fig. 3g) . The secretion efficiency of TNF-a was lower in SIRT6 KD THP-1 cells than in control KD cells, especially when the cells were supplemented with palmitic acid (Fig. 3g) . Similar results were obtained for TNF-a in mouse macrophages. TNF-a in SIRT6 WT macrophages had lower lysine fatty acylation than in SIRT6 KO macrophages (Fig. 3h) , whereas TNF-a secretion efficiency in SIRT6 WT macrophages was higher than in SIRT6 KO macrophages (Fig. 3i) .
SIRT6 was reported to be mainly localized in the nucleus 9 . The regulation of TNF-a secretion by SIRT6 indicated that SIRT6 might be present in secretory organelles, such as the endoplasmic reticulum. We indeed detected SIRT6 in the endoplasmic reticulum fraction of MEF and THP-1 cell lysates (Supplementary Fig. 9 ). In SIRT6 KD THP-1 cells or SIRT6 KO MEF cells, less or no SIRT6 was detected in the endoplasmic reticulum fraction compared with SIRT6 WT cells (Supplementary Fig. 9 ). The presence of SIRT6 in the endoplasmic reticulum provided further support for the conclusion that SIRT6 regulates TNF-a secretion through defatty-acylation of TNF-a.
In summary, our enzymological and structural studies show that human SIRT6, which has weak deacetylase activities in vitro, catalyses the hydrolysis of fatty acyl lysine modifications more efficiently than deacetylation. SIRT6 regulates the fatty acylation level on K19 and K20 of TNF-a and this modulates the secretion of TNF-a. It has been reported that SIRT6 regulates the acetylation level on histone H3K9 and K56 9, 11, 12 . Our results are not in conflict with these reports because it is possible that the association with chromatin can regulate the activity of SIRT6. Alternatively, fatty acylation of lysine residues may occur to histones 22, 23 , and SIRT6 can regulate both acetylation and fatty acylation of histones. The significance of our finding is several fold. First, it reveals a novel physiological activity for SIRT6. Second, it demonstrates, as far as we know for the first time, that lysine fatty acylation, a protein post-translational modification that has been little studied until now, has an important role in regulating protein secretion. Other proteins (Supplementary Fig. 10 ), such as insulin-like growth factor 1 (IGF1) may be regulated by similar mechanisms 6, 24 . Third, the discovery of SIRT6 activity on protein lysine fatty acylation provides an avenue to further investigate this under-recognized of using Alk14 to detect TNF-a fatty acylation. b, SIRT6 controls TNF-a fatty acylation on K19 and K20. KR, TNF-a(K19R, K20R) mutant. c, H133 of SIRT6 is required for TNF-a defatty-acylation. KI, knock-in. d, SIRT6 defatty-acylates TNF-a in vitro. e, SIRT6 regulates secretion of TNF-a in MEF cells. n 5 6; ***P , 0.001. f-i, SIRT6 regulates fatty acylation level and secretion of endogenous TNF-a in THP-1 cells (f and g; n 5 3; **P , 0.01) and bonemarrow-derived macrophages (h and i; n 5 5; *P , 0.02). Secretion data were expressed as mean 6 s.d. IP, immunoprecipitation; shRNA, short hairpin RNA; WB, western blot.
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protein modification 16, 17 and may reveal interesting connections to the well-known cysteine palmitoylation and N-terminal glycine myristoylation 25 .
METHODS SUMMARY
Expression, purification and crystallization. Human SIRT6 was overexpressed in Escherichia coli and purified using Ni-NTA affinity chromatography, ion exchange and gel filtration. Crystals were grown from 12% PEG6K, 0.1 M MES (2-(N-morpholino)ethanesulphonic acid), pH 6.5. Data collection and structure determination. Data were collected at the Shanghai Synchrotron Radiation Facility (SSRF). The structure was determined by molecular replacement. Activity assay of SIRT6 on different acyl peptides. Acyl peptides were synthesized as previously described 5 . The hydrolysis of different acyl peptides catalysed by SIRT6 was monitored by high-performance liquid chromatography. Kinetic parameters were determined by varying the concentrations of the acyl peptides. Detection of long-chain fatty acylation on TNF-a. Flag-tagged TNF-a was transiently transfected into either SIRT6 WT or KO MEF cells 7 . Endogenous TNF-a in THP-1 cells and SIRT6 WT or KO mouse macrophages was stimulated by LPS. The fatty acyl lysine modification was detected using alkyne-tagged fatty acid analogue Alk14 using a procedure modified from a previously published method 21 .
Full Methods and any associated references are available in the online version of the paper. 
METHODS
Reagents. Mouse monoclonal anti-Flag M2 antibody conjugated with horseradish peroxidase, anti-Flag M2 affinity gel, and human/mouse SIRT6 antibody (S4322) were from Sigma. Human TNF-a antibody (D5G9) and mouse TNF-a antibody (D2D4) were from Cell Signaling Technology. TNF-a Affibody immobilized on agarose (ab31909) and human SIRT6 antibody (ab88494) were from Abcam. Lamin A/C antibody (636), b-actin antibody (C4) and GRP 78 antibody (H-129) were from Santa Cruz Biotechnology. The rabbit pan-specific anti-acetyl lysine antibody was from ImmuneChem Pharmaceuticals. The goat anti-rabbit and mouse IgG conjugated with horseradish peroxidase and protein A/G plus-agarose were from Santa Cruz Biotechnology. Human and mouse TNF-a ELISA kits were from eBioscience. Brefeldin A (BFA), phorbol 12-myristate 13-acetate (PMA), lipopolysaccharides from Escherichia coli 0111:B4 (LPS) and palmitic acid were purchased from Sigma. Alk14 was synthesized according to reported procedures 21 . SIRT6 WT or KO MEF cells were generated as previously reported 7 . THP-1 cells were purchased from ATCC. Cloning, expression and purification of full-length SIRT6 for activity assay. The open reading frame of full-length human SIRT6 (1-355) was inserted into a pET28a vector between the BamHI and NotI sites. This plasmid was transformed into E. coli Arctic Express (DE3) cells. The cells were cultured at 37 uC in 2 3 YT culture medium (5 g of NaCl, 16 g of bactotrypton and 10 g of yeast extract per litre). Isopropyl-b-D-1-thiogalactopyranoside (IPTG, 0.2 mM) was used to induce expression when attenuance D 600 nm was 0.6, and the culture was grown for 20 h at 289 K. Cells were collected by centrifugation at 7,330g for 10 min and then re-suspended in lysis buffer (20 mM Tris-HCl, pH 7.2, 500 mM NaCl and 2% glycerol). Cells were lysed using a cell disrupter. After centrifugation at 29,300g for 25 min at 277 K, the supernatant was loaded onto a nickel column (QFFSepharose, Amersham Biosciences) pre-equilibrated with 20 mM Tris-HCl pH 7.2 with 500 mM NaCl. The protein was eluted with a linear gradient of imidazole (0-500 mM). The desired fractions were pooled, concentrated and buffer exchanged to cation exchange buffer (20 mM Tris pH 7.2, 80 mM NaCl, 5% glycerol). The protein was loaded onto a cation exchange column (Amersham Biosciences) and eluted with 1 M NaCl, 20 mM Tris-HCl, pH 7.2, 2% glycerol. The purified protein was stored at 280 uC. Cloning, expression and purification of truncated SIRT6 for crystallization. Human SIRT6 (1-294) was inserted into a pET28a vector between the NdeI and NotI sites. The protein was overproduced at 37 uC in E. coli Rosetta (DE3) strain using 2 3 YT medium. The expression and purification method was the same as that used for the full-length SIRT6 except that after Ni column purification the protein was further purified by gel filtration using a Superdex75 column (Amersham Biosciences). The protein was eluted with 20 mM Tris-HCl, pH 7.0, 100 mM NaCl. After concentration to 8 mg ml 21 , the target protein was frozen at 280 uC. Synthesis of acyl peptides. The peptides were synthesized and purified as described previously 5 The identity of the peptides was confirmed using LCQ Fleet ThermoFisher Mass Spectrometer. The acetyl, butyryl peptides were dissolved in 25% (v/v) DMSO in water. The longer chain fatty acyl peptides were dissolved in DMSO. The concentrations of peptides were determined at 280 nm using extinctions coefficient of the two tryptophans attached at the C termini of the peptides. Deacylation activity assay. The activity of SIRT6 was analysed using reverse phase high-performance liquid chromatography on a Kinetex XB-C18 column (100A, 75 mm 3 4.60 mm, 2.6 mm, Phenomenex). SIRT6 full length (1 mM) was incubated in a reaction mixture (60 ml) containing 20 mM Tris pH 8.0, 1 mM DTT, 0.5 mM NAD and 50 mM H3K9 acyl peptides at 37 uC for 30 min. Total DMSO content in the reaction was ,2.5% unless mentioned otherwise. The reactions were quenched with 60 ml of 0.5 N HCl in methanol. The reactions were then monitored by high-performance liquid chromatography as described later in the kinetics assay. Kinetics assay for acetyl and butyryl peptides. Peptide concentrations were varied from 0 to 250 mM for H3K9 butyryl peptide and from 0 to 600 mM for the acetyl peptide. The reaction mixtures (60 ml with 2 mM NAD, 1 mM DTT, 20 mM Tris, pH 8.0, 4 mM SIRT6 full length, and acyl peptides at various concentrations) were incubated for 30 min at 37 uC.The reaction was stopped using 60 ml of 0.5 N HCl in methanol. The reaction mixtures were spun at 18,000g for 10 min and were analysed on a Kinetex XB-C18 column (100A, 100 mm 3 4.60 mm, 2.6 mm, Phenomenex). The gradient of 20-40% B (acetonitrile with 0.1% TFA) in 17 min at 0.5 ml min 21 was used. Kinetics assay for long-chain fatty acyl peptides. The peptide concentrations were varied from 1 to 20 mM. The reactions (60 ml with 2 mM NAD, 1 mM DTT, 20 mM Tris pH 8.0, 0.2 mM recombinant SIRT6 full length, and acyl peptides at different concentrations) was incubated for 15 min at 37 uC. The reaction was stopped using 60 ml of 0.5N HCl in methanol. The reaction mixtures were spun at 18,000g for 10 min and were analysed on a Kinetex XB-C18 column (100A, 75 mm 3 4.60 mm, 2.6 mm, Phenomenex). The gradient of 0-55% B in 10 min at 0.5 ml min 21 was used. The product and the substrate peaks were quantified using absorbance at 280 nm and converted to initial rates, which were then plotted against the acyl peptide concentrations and fitted using Kaleidagraph. Crystallization, X-ray data collection and structure determination. Crystals of complex SIRT6 with H3K9-Myr and ADPR were obtained by hanging drop vapour-diffusion method at 291 K using commercial screens from Hampton Research. Each drop consisting of 1 ml of 10 mg ml 21 protein complex solution (20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 5 mM DTT) and 1 ml reservoir solution was equilibrated against 400 ml reservoir solution. The qualified crystals of SIRT6 grew with a cube profile within 1 week with a reservoir containing 12% PEG6K, 0.1 M MES, pH 6.5. The mixture of 30% glycerol with reservoir solution above was used as cryogenic liquor. The X-ray diffraction data were collected at 100 K in a liquid nitrogen gas stream at the Shanghai Synchrotron Radiation Facility BL17U. 180 frames were collected with a 1u oscillation and the data were indexed and integrated using the program HKL2000
26
. The complex structure of SIRT6 with H3K9 myristoyl peptide and ADPR was solved by molecular replacement using the program Molrep from the CCP4 Suite 27 with the published SIRT6 structure (PDB: 3K35) 28 as the search model. Refinement and model building were performed with REFMAC5 and COOT from CCP4. The X-ray diffraction data collection and structure refinement statistics are shown in Supplementary Table 1 . Generation of SIRT6 KO MEF cells with human SIRT6 WT and H133Y mutant knock-in. Human SIRT6 WT or H133Y complementary DNA was inserted to lentiviral vector (engineered from pSIN-EF2-OCT4 vector with OCT4 deletion to convert into gateway destination vector, and provided by C. Zhang) using Gateway Cloning. After co-transfection of SIRT6 WT or H133Y lentiviral plasmid, pCMV-dR8.2, and pMD2.G into 293T cells, the medium was collected to infect SIRT6 KO MEF cells. The SIRT6 WT or H133Y knock-in cells were selected using 1.5 mg ml 21 puromycin in complete cell culture medium. Overexpressed SIRT6 WT and H133Y mutant have a C-terminal V5 tag. Cloning of TNF-a. For construction of human TNF-a expression vector to express wild-type TNF-a protein (TNF-a WT) with N-terminal Flag tag and C-terminal haemagglutinin tag, human full-length TNF-a cDNA were generated by PCR and inserted into pCMV4A vector at EcoRV and XhoI sites. The plasmid of TNF-a double lysine mutant (K19R, K20R), TNF-a KR, was made by overlap extension PCR. Transfection of TNF-a into MEF cells. SIRT6 WT and KO MEF cells were maintained in DMEM medium containing glucose and L-glutamine (Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen). The pCMV vectors containing target genes were transfected into cells using FuGene 6 (Promega) according to the manufacturer's protocol. Empty pCMV vector was transfected into cells as negative control. This transfection method was also applied to SIRT6 KO MEF cells with human SIRT6 WT or H133Y mutant knock-in for TNF-a overexpression. Labelling of TNF-a in MEF cells with Alk14. SIRT6 WT or KO MEF cells were cultured with fresh medium containing 20 mM Alk14 and 5 mg ml 21 brefeldin A for 12 h after transient transfection of TNF-a. Cells without Alk14 or without overexpression of TNF-a were used as negative controls. Cells were collected by cell scraper and resuspended in 1 3 PBS buffer. After centrifugation at 500g for 5 min at 4 uC, the cell pellet was dissolved in lysis buffer (25 mM Tris, pH 7.4, 150 mM NaCl, 10% glycerol, 1% Nonidet P-40) with protease inhibitor cocktail (Sigma). The supernatant was collected after centrifugation at 16,000g for 10 min at 4 uC, and used for western blotting, immunoprecipitation or TNF-a ELISA experiment. Generation of stable SIRT6 KD THP-1 cells. SIRT6 shRNA lentiviral plasmids in pLKO.1-puro vector were purchased from Sigma. SIRT6 shRNA 1 (TRCN0000378253) ccggcagtacgtccgagacacagtcctcgaggactgtgctcggacgtactgtttttg and shRNA 2 (TRCN0000232528) ccgggaagaatgtgccaagtgtaagctcgagcttacacttggcacattcttctttttg were used. After co-transfection of SIRT6 shRNA plasmid, pCMV-dR8.2 and pMD2.G into 293T cells, the medium was collected to infect THP-1 cells. The SIRT6 KD cells were selected using 1.5 mg ml 21 puromycin in complete cell culture medium. THP-1 cells infected with lentivirus containing control shRNA plasmid were carried out similarly. Labelling of TNF-a in THP-1 cells with Alk14. THP-1 cells (with control shRNA, SIRT6 shRNA 1 orSIRT6 shRNA 2, at 0.6 3 10 6 cells ml
21
) were treated with PMA (200 ng ml 21 ) for 24 h. Then cells were cultured with fresh medium containing Alk14 (50 mM) and LPS (1 mg ml
). After 1 h, brefeldin A was added to culture medium (5 mg ml
). Cells were collected after 10 h, and dissolved in lysis buffer (25 mM Tris, pH 7.4, 150 mM NaCl, 10% glycerol, 1% Nonidet P-40) with protease inhibitor cocktail (Sigma). The supernatant was collected after centrifugation at 16,000g for 10 min at 4 uC and used for western blotting or immunoprecipitation.
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